NASDAQ:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free IDXG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.42▼$1.4350-Day Range$4.75▼$10.4052-Week Range$2.57▼$10.42Volume2,378 shsAverage Volume5,307 shsMarket Capitalization$6.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsHeadlinesSocial MediaStock AnalysisCompetitorsEarningsHeadlinesSocial Media Get Interpace Biosciences alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Interpace Biosciences Stock (NASDAQ:IDXG)Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. IDXG Stock News HeadlinesApril 3, 2024 | seekingalpha.comPDI Under $20 Exceeds A 13% Yield With Potential Upside On The HorizonMarch 7, 2024 | msn.comInterpace Biosciences announces preliminary Q4 revenue of $10.3MApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 7, 2024 | globenewswire.comInterpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business ResultsMarch 1, 2024 | seekingalpha.comPDI: What Lurks Under The Hood Of PIMCO's Crown JewelFebruary 22, 2024 | benzinga.comInterpace Biosciences Stock (OTC:IDXG) Dividends: History, Yield and DatesJanuary 24, 2024 | seekingalpha.comPDI: 14% Yield, But Risks Are Rising (Rating Downgrade)January 9, 2024 | seekingalpha.comPDI Looks Like It Bottomed And Is Still Yielding Over 14%April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? December 5, 2023 | seekingalpha.comPDI: Lag Likely To ContinueNovember 8, 2023 | finance.yahoo.comInterpace Biosciences Announces Record Third Quarter 2023 Financial and Business ResultsOctober 24, 2023 | seekingalpha.comPDI: Pain Could Be On The HorizonOctober 1, 2023 | seekingalpha.comPDI: Pricing Improves, Fundamentals Stay Poor, We UpgradeAugust 31, 2023 | seekingalpha.comPDI: 100 Big Yield CEFs, REITs, MLPs - These 3 Worth ConsideringAugust 10, 2023 | finanznachrichten.deInterpace Biosciences, Inc.: Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business ResultsAugust 9, 2023 | finance.yahoo.comInterpace Biosciences Announces Record Second Quarter 2023 Financial and Business ResultsJuly 10, 2023 | finance.yahoo.comInterpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® ReimbursementJune 5, 2023 | finance.yahoo.comInterpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023May 13, 2023 | finanznachrichten.deInterpace Biosciences, Inc.: Interpace Biosciences Announces Record First Quarter 2023 Financial and Business ResultsMay 12, 2023 | finance.yahoo.comInterpace Biosciences Announces Record First Quarter 2023 Financial and Business ResultsMarch 28, 2023 | finanznachrichten.deInterpace Biosciences, Inc.: Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business ResultsMarch 27, 2023 | finance.yahoo.comInterpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business ResultsMarch 13, 2023 | seekingalpha.comPDI And PTY: Unwelcome ROC, Buyer BewareMarch 9, 2023 | financialpost.comPriestly Demolition Inc. Promotes Leaders in a Restructuring Plan Designed to Support the Expansion of the Company Across North AmericaMarch 6, 2023 | financialpost.comWestport Signs Third Global Heavy-Duty OEM Collaboration Agreement to Demonstrate H2 HPDI™ Fuel System on IC Engine PlatformFebruary 20, 2023 | seekingalpha.comPTY And PDI: Abysmal SetupsJanuary 31, 2023 | gurufocus.comSeascape Capital Management Buys 3, Sells 2 in 4th QuarterSee More Headlines Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2023Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Services Current SymbolNASDAQ:IDXG CUSIP69329V10 CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$800,000.00 Net Margins1.99% Pretax Margin2.81% Return on Equity-1.79% Return on Assets7.53% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual Sales$40.21 million Price / Sales0.15 Cash Flow$0.58 per share Price / Cash Flow2.45 Book Value($14.16) per share Price / Book-0.10Miscellaneous Outstanding Shares4,370,000Free Float4,086,000Market Cap$6.22 million OptionableNot Optionable Beta0.64 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Thomas W. Burnell Ph.D. (Age 58)Pres, CEO & Director Comp: $425kMr. Thomas John Freeburg Ph.D. (Age 52)Chief Accounting Officer, CFO, Treasurer & Sec. Dr. Sydney D. FinkelsteinChief Scientific OfficerDr. Alidad Mireskandari M.B.A.Ph.D., Chief Devel. OfficerMr. Patrick KaneVP & Corp. ControllerKey CompetitorsAvingerNASDAQ:AVGRPlus TherapeuticsNASDAQ:PSTVVivos TherapeuticsNASDAQ:VVOSVenus ConceptNASDAQ:VEROAcutus MedicalNASDAQ:AFIBView All Competitors IDXG Stock Analysis - Frequently Asked Questions When is Interpace Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our IDXG earnings forecast. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (NASDAQ:IDXG) issued its earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.26. The business services provider earned $8.33 million during the quarter. Interpace Biosciences had a net margin of 1.99% and a negative trailing twelve-month return on equity of 1.79%. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD). This page (NASDAQ:IDXG) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
